Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Watch

A Vaccine Enhances CAR-T Cell Efficacy against Solid Tumors

DOI: 10.1158/2159-8290.CD-RW2020-007 Published February 2020
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major Finding: Claudin 6 (CLDN6) may represent a novel target for CAR-T cell therapies aimed at solid tumors.

  • Concept: A combination of a CAR-T cell–amplifying vaccine and CLDN6 CAR-T cells was effective in mice.

  • Impact: CLDN6 as a CAR-T target and vaccines to enhance CAR-T efficacy both warrant further investigation.

Chimeric antigen receptor (CAR)-T cell therapy has revolutionized care in some blood cancers, but establishing these treatments in solid tumors has been difficult. Reinhard, Rengstl, Oehm, and colleagues developed a CAR targeting claudin 6 (CLDN6), a transmembrane tight-junction protein that their findings suggest is normally expressed only in fetal tissues in humans but is highly overexpressed in some tumor types. When treated with CLDN6-targeting human CAR-T cells, mice xenografted with human tumor-cell lines exhibited complete tumor regression, whereas control-treated tumors progressed rapidly. To enhance engraftment and persistence of the CAR-T cells, a major barrier to treatment of solid tumors with CAR-T cell therapies, the authors employed a liposomal CLDN6-encoding vaccine (CLDN6-LPX) to enhance CLDN6-specific T-cell expansion. In vitro, exposure to CLDN6-LPX triggered display of CLDN6 on dendritic cells that led to stimulation, cytokine secretion, and proliferation of cocultured CLDN6 CAR-T cells. Correspondingly, in vivo intravenous injection of CLDN6-LPX increased surface expression of CLDN6 on splenic dendritic cells. Further, mice engrafted with CLDN6 CAR-T cells exhibited increased proportions of CLDN6 CAR-T cells following CLDN6-LPX treatment. CLDN6-LPX caused a marked expansion of circulating CLDN6 CAR-T cells in vivo, even when the number of CAR-T cells transferred was small. Additionally, CLDN6-LPX was capable of causing reexpansion of CLDN6 CAR-T cells after prolonged treatment-free intervals, revealing memory formation. Further, in mice bearing large Lewis lung tumors or colon carcinomas, adoptive cell transfer with subtherapeutic doses of CLDN6 CAR-T cells caused complete regression of large tumors and greater median survival when CLDN6-LPX was added to the treatment regimen, and the combination treatment also caused complete tumor regression in xenografted mice. This study illustrates the potential not only of using CLDN6 as a CAR-T target, but also of combining vaccines such as CLDN6-LPX with CAR-T therapy.

Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science 2020 Jan 2 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2020 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 10 (2)
February 2020
Volume 10, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Vaccine Enhances CAR-T Cell Efficacy against Solid Tumors
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Vaccine Enhances CAR-T Cell Efficacy against Solid Tumors
Cancer Discov February 1 2020 (10) (2) 171; DOI: 10.1158/2159-8290.CD-RW2020-007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Vaccine Enhances CAR-T Cell Efficacy against Solid Tumors
Cancer Discov February 1 2020 (10) (2) 171; DOI: 10.1158/2159-8290.CD-RW2020-007
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • Epstein–Barr Virus–Induced Antitumor Immune Response May Be Harnessable
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
Show more Research Watch

Immunotherapy

  • PCSK9 Causes MHC Class I Lysosomal Degradation to Promote Tumor Growth
  • Immune-Checkpoint Blockade Induces Colitis via Immune-Cell Alterations
  • Modified IL18 Overcomes a Barrier to IL18-Based Immunotherapy Efficacy
Show more Immunotherapy
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement